Recurrence of primary cutaneous CD30-positive lymphoproliferative disorder following COVID-19 vaccination

Caitlin M Brumfiel; Meera H Patel; David J DiCaudo; Allison C Rosenthal; Mark R Pittelkow; Aaron R Mangold

doi:10.1080/10428194.2021.1924371

Recurrence of primary cutaneous CD30-positive lymphoproliferative disorder following COVID-19 vaccination

Leuk Lymphoma. 2021 Oct;62(10):2554-2555. doi: 10.1080/10428194.2021.1924371. Epub 2021 May 11.

Authors

Caitlin M Brumfiel¹, Meera H Patel¹, David J DiCaudo¹, Allison C Rosenthal², Mark R Pittelkow¹, Aaron R Mangold¹

Affiliations

¹ Department of Dermatology, Mayo Clinic Arizona, Scottsdale, USA.
² Department of Medicine, Division Hematology-Oncology, Phoenix, USA.

PMID: 33974494
DOI: 10.1080/10428194.2021.1924371

No abstract available

Keywords: CD30-positive lymphoproliferative disorder; COVID-19 vaccination; COVID-19 vaccine; Lymphoma; lymphoproliferative disorder; mRNA vaccine.

Publication types

Letter

MeSH terms

COVID-19 Vaccines
COVID-19*
Humans
Ki-1 Antigen
Lymphoma, T-Cell, Cutaneous*
Lymphomatoid Papulosis*
Lymphoproliferative Disorders* / diagnosis
Lymphoproliferative Disorders* / etiology
Neoplasm Recurrence, Local
SARS-CoV-2
Skin Neoplasms*
Vaccination

Substances

COVID-19 Vaccines
Ki-1 Antigen